Sheldon H. Preskorn, M.D., is President and Chief
Executive Officer for the Clinical
Research Institute and Professor in the Department of
Psychiatry at the University
of Kansas School of Medicine-Wichita (KUSM-W).
A fellow of the American Psychiatric Association and the
American Psychopathological Association, Dr. Preskorn has
served on advisory committees of the Food and Drug Administration,
Veterans Administration, National Institutes of Health and
National Science Foundation, and was a consultant to the Menninger
Foundation on clinical psychopharmacology.
He received his MD degree at the University of Kansas, Kansas
City, Kansas. He completed a two-year residency in anatomical
pathology (with emphasis on neuropathology) and a one-year
rotating internship in internal medicine and psychiatry at
the University of Kansas Medical Center, Kansas City, Kansas
and his residency in psychiatry at Washington University School
of Medicine, St. Louis, Missouri. He has undergraduate degree
in psychobiology (psychology, biology and chemistry) and postgraduate
medical training in anatomical pathology (neuropathology),
psychiatry, and basic and clinical pharmacology.
An international lecturer and the author of over 400 scientific,
professional articles and books. Dr. Preskorn has received
continuous grant funding since 1978 for an estimated life-time
total of 50 million dollars. This funding has allowed him
to pursue research in psychopharmacology and neuroscience
of psychiatric illnesses.
His basic pharmacological and neuroscience research has included
studies in learning theory, neurochemistry, neurophysiology,
histochemistry, electron microscopy, cerebral blood flow and
metabolism, positron emission tomography and radioligand binding.
His clinical research has included pharmacokinetics, drug-drug
interactions, and drug development through all clinical phases
from "first time in man" studies through phase III
trials. He has been the principal investigator on over 250
clinical trials including drug development studies of all
antidepressants marketed in the United States in the last
25 years. He also has extensive experience with the drug registration
process having been involved in the registration process for
8 of the 12 antidepressants marketed in the United States
over the last 25 years and the only implantable device approved
for the treatment of a psychiatric illness.
In addition to this research work, his clinical and administrative
experience includes six years as supervising physician for
an acute psychosis ward, six years as chief of psychiatry
for a university affiliated Veterans Administration Medical
Center, five years as director of the KUSM-W Outpatient Psychiatric
Clinic and eight years as Chair of the KUSM-W Department of